Table 4.
Cumulative incidence and Cox regression analysis of type 2 diabetes over time in participants with breast cancer stratified by receipt of hormone therapy
| Variable | Incidence/1,000 person‐years | Crude HR (95% CI) | Adjusted HR† (95% CI) | |
|---|---|---|---|---|
| Hormonal therapy | No hormonal therapy | Hormonal therapy vs no hormonal therapy | Hormonal therapy vs no hormonal therapy | |
| Year 1 | 106.2 | 75.1 | 1.24 (0.88–1.75) | 1.22 (0.86–1.74) |
| Year 2 | 89.2 | 49.9 | 1.06 (0.77–1.45) | 1.05 (0.76–1.45) |
| Year 3 | 84.2 | 41.4 | 1.05 (0.77–1.42) | 1.05 (0.77–1.44) |
| Year 4 | 80.5 | 38.8 | 1.02 (0.76–1.36) | 1.03 (0.76–1.39) |
| Year 5 | 79.0 | 36.3 | 1.05 (0.79–1.40) | 1.08 (0.81–1.45) |
| Year 6 | 76.9 | 34.9 | 1.04 (0.78–1.37) | 1.07 (0.80–1.42) |
| Year 7 | 75.4 | 33.8 | 1.03 (0.78–1.36) | 1.05 (0.79–1.40) |
| Year 8 | 73.7 | 33.6 | 0.99 (0.75–1.31) | 1.01 (0.77–1.34) |
| Year 9 | 72.4 | 33.0 | 0.98 (0.74–1.28) | 1.00 (0.75–1.32) |
| Year 10 | 71.7 | 31.7 | 0.99 (0.75–1.30) | 1.01 (0.77–1.34) |
| Year 11 | 70.9 | 31.6 | 0.98 (0.74–1.28) | 0.99 (0.75–1.30) |
| Year 12 | 70.5 | 31.2 | 0.99 (0.75–1.29) | 1.00 (0.76–1.32) |
| Year 13 | 70.3 | 30.9 | 1.00 (0.76–1.31) | 1.01 (0.77–1.33) |
| Year 14 | 70.0 | 30.5 | 1.00 (0.76–1.31) | 1.01 (0.77–1.33) |
| Year 15 | 69.9 | 30.3 | 1.00 (0.76–1.31) | 1.01 (0.77–1.33) |
Censored cases were defined as follows: (i) recurrence of breast cancer (surgery for breast cancer at 1 year after the index date); (ii) the presence of new cancer or metastasis; (iii) death; and (iv) end of observation (follow up for 1–10 years after the index date). †Model adjusted for age, income, cancer stage, Charlson Comorbidity Index, and history of hyperlipidemia, hypertension and cardiovascular disease. CI, confidence interval; HR, hazard ratio.